OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	145
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	99
Advances in the discovery of drugs that treat pulmonary arterial hypertension	76
Advances in ion channel high throughput screening: where are we in 2023?	72
Strategies for targeting RNA with small molecule drugs	67
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	63
γ-Secretase: once and future drug target for Alzheimer’s disease	62
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	58
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	40
Methods in marine natural product drug discovery: what’s new?	38
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	38
What is the plausibility that all drugs will be designed by computers by the end of the decade?	38
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	37
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	32
Tools and techniques for the discovery of therapeutic aptamers: recent advances	31
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	31
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	31
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	29
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	29
Virtual screening: hope, hype, and the fine line in between	29
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	28
A cautionary tale of paradox and false positives in cannabidiol research	28
The rules often neglected in current medicinal chemistry	27
Guided structure-based ligand identification and design via artificial intelligence modeling	26
Water in drug design: pitfalls and good practices	25

Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	25
An update on knowledge graphs and their current and potential applications in drug discovery	25
Molecular hybridization: a powerful tool for multitarget drug discovery	25